文献速递甲状腺疾病

美国甲状腺乳头状癌手术延迟与生存:一项SEER-Medicare分析

Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究基于1999至2018年SEER-Medicare链接数据,纳入8170例接受甲状腺切除术的甲状腺乳头状癌(PTC)医疗保险受益人,分析手术时间与生存的关系。结果显示,手术延迟超过180天与总生存(OS)死亡率升高相关(aHR 1.24;95%CI 1.01-1.53),在局限期病变中延迟91-180天和超过180天的OS风险分别增加25%和61%,超过180天的疾病特异性生存(DSS)死亡率约为对照的3.5倍。结论提示,在淋巴结转移前的局限期病变中,手术延迟可能影响OS和DSS。

要点

  • 8170例PTC患者中,89.8%在90天内手术,7.8%在91-180天,2.4%超过180天。
  • 手术延迟超过180天与OS死亡率升高相关(aHR 1.24;95%CI 1.01-1.53)。
  • 局限期病变延迟超过180天者DSS死亡率约为对照的3.5倍(aHR 3.51;95%CI 1.68-7.32)。

核心结论

  • 在淋巴结转移前的局限期病变中,PTC手术延迟可能影响OS和DSS。

研究设计与样本

  • 基于1999至2018年SEER-Medicare链接数据的分析,纳入8170例接受甲状腺切除术的PTC医疗保险受益人,平均年龄69.3岁(SD±11.4)。

主要发现

  • 8170例PTC患者中,89.8%在诊断后90天内手术,7.8%在91至180天手术,2.4%在180天后手术。
  • 手术时间延长与OS死亡率升高相关:超过180天组aHR 1.24(95%CI 1.01-1.53)。
  • 按摘要分期分层,局限期病变91-180天组OS风险增加25%(aHR 1.25;95%CI 1.05-1.51),超过180天组OS风险增加61%(aHR 1.61;95%CI 1.19-2.18)。
  • 局限期病变超过180天组DSS死亡率约为对照的3.5倍(aHR 3.51;95%CI 1.68-7.32)。
  • 按T分期分层,T2病变超过180天组全因死亡率约为对照的2倍(aHR 2.0;95%CI 1.1-3.3),疾病特异性死亡率约为对照的2.7倍(aHR 2.7;95%CI 1.05-6.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Delays in surgery and their impact on survival in papillary thyroid cancer (PTC) is unclear. We sought to investigate the association between time to surgery and survival in patients with PTC. METHODS: A total of 8170 Medicare beneficiaries with PTC who underwent thyroidectomy were identified within the Surveillance, Epidemiology, and End Results-Medicare linked data files between 1999 and 2018. Disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meir analysis, and Cox proportional hazards models were specified to estimate the association between time to surgery and survival. RESULTS: Among 8170 patients with PTC, mean age 69.3 (SD+/- 11.4), 89.8% had surgery within the first 90 days, 7.8% had surgery 91 to 180 days from diagnosis, and 2.4% had surgery after 180 days. Increasing time to surgery was associated with increased mortality for OS in the >180-day group [adjusted hazard ratio (aHR) 1.24; 95% CI, 1.01-1.53]. Moreover, on stratification by summary stage, those with localized disease in the 91- to 180-day group increased risk by 25% (aHR 1.25; 95%CI, 1.05-1.51), and delaying over 180 days increased risk by 61% (aHR 1.61; 95%CI, 1.19-2.18) in OS. Those with localized disease in the >180-day group had almost 4 times the estimated rate of DSS mortality (aHR3.51; 95%CI, 1.68-7.32). When stratified by T stage, those with T2 disease in the >180 days group had double the estimated rate of all-cause mortality (aHR 2.0; 95% CI, 1.1-3.3) and almost triple the estimated rate of disease-specific mortality (aHR 2.7; 95% CI, 1.05-6.8). CONCLUSIONS: Delays in surgery for PTC may impact OS and DSS in localized disease, prior to nodal metastasis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chaves N, Broekhuis JM, Fligor SC, et al. Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis. J Clin Endocrinol Metab. 2023. PMID: 36987566. doi:10.1210/clinem/dgad163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。